Gallstone formation and hepatobiliary tumour risk: Clinical implications of the bile acid–gut microbiota axis
- 1Department of Hepatobiliary Pancreatic, Thyroid and Breast Surgery Yiling People's Hospital Yichang China
- 2Department of Organ Procurement Organization Institute of Hepatobiliary Diseases of Wuhan University Zhongnan Hospital of Wuhan University Wuhan China
Abstract
Background Gallstones affect approximately 6%–15% of adults worldwide and represent a common condition that also serves as a risk factor for hepatobiliary malignancies. Conventional ultrasound cannot provide early warning during the early metabolic phase before crystallization occurs. Methods This narrative review provides a critical synthesis of the mechanisms, clinical evidence, and translational perspectives of the bile acid–gut microbiota axis in gallstone development and hepatobiliary tumour risk. Relevant publications up to September 2026 were identified through searches of MEDLINE/PubMed, EMBASE, and Web of Science, with additional manual screening of reference lists. Randomized clinical trials, systematic reviews, meta‐analyses, key mechanistic studies, and guidelines were preferentially included. Results Patients with gallstones exhibit characteristic alterations, including elevated serum glycocholic acid (+ 0.83 µmol/L) and taurocholic acid (+ 0.51 µmol/L), reduced microbial diversity (Proteobacteria accounting for 91.59%), and a 2.5 ‐ fold increase in bai gene cluster abundance (r = 0.609). Conjugated bile acids show a dose‐response relationship with hepatocellular carcinoma risk (OR = 1.28–5.62), while late breakfast increases gallstone risk (OR = 1.435). The combination of dried blood spot sampling (R2 > 0.92) and AI‐based prediction models (AUC = 0.82–0.90) offers a feasible approach for dynamic monitoring. Conclusions This review proposes a three‐tiered stratified management strategy—DBS sampling, targeted metabolomics, and AI assessment—to provide a clinical translational reference for early warning and precision prevention of gallstones and hepatobiliary tumours.
Related
- The Gut Microbiota-Immunity Axis in Colorectal Cancer: Implications for Immunotherapy and Clinical Translation.
- Gut microbiota in esophageal cancer: mechanisms, clinical implications, and therapeutic potential
- Viral-Gut Microbiota Interactions: Implications for the Gut Mucosa in Inflammatory Bowel Disease.
- Gut microbiota and intestinal permeability in rheumatoid arthritis: therapeutic implications and future directions
- Bariatric surgery-induced gut microbiota remodeling and innate immune activation: implications for gastrointestinal cancer immunotherapy
BibTeX
@article{li2026gallstone,
title = {{Gallstone formation and hepatobiliary tumour risk: Clinical implications of the bile acid–gut microbiota axis}},
author = {Rui Li and Yong Zhang and Kaishuang Cai and Shaojun Deng and Chaofeng Tan and Yunjie Li and Wenjin Liang},
journal = {Clinical and Translational Discovery},
year = {2026},
month = oct,
doi = {10.1002/ctd2.70207},
url = {https://doi.org/10.1002/ctd2.70207},
note = {CC BY},
}
RIS
TY - JOUR
TI - Gallstone formation and hepatobiliary tumour risk: Clinical implications of the bile acid–gut microbiota axis
AU - Rui Li
AU - Yong Zhang
AU - Kaishuang Cai
AU - Shaojun Deng
AU - Chaofeng Tan
AU - Yunjie Li
AU - Wenjin Liang
PY - 2026
DA - 2026/10/26
JO - Clinical and Translational Discovery
DO - 10.1002/ctd2.70207
UR - https://doi.org/10.1002/ctd2.70207
AB - Background Gallstones affect approximately 6%–15% of adults worldwide and represent a common condition that also serves as a risk factor for hepatobiliary malignancies. Conventional ultrasound cannot provide early warning during the early metabolic phase before crystallization occurs. Methods This narrative review provides a critical synthesis of the mechanisms, clinical evidence, and translational perspectives of the bile acid–gut microbiota axis in gallstone development and hepatobiliary tumour risk. Relevant publications up to September 2026 were identified through searches of MEDLINE/PubMed, EMBASE, and Web of Science, with additional manual screening of reference lists. Randomized clinical trials, systematic reviews, meta‐analyses, key mechanistic studies, and guidelines were preferentially included. Results Patients with gallstones exhibit characteristic alterations, including elevated serum glycocholic acid (+ 0.83 µmol/L) and taurocholic acid (+ 0.51 µmol/L), reduced microbial diversity (Proteobacteria accounting for 91.59%), and a 2.5 ‐ fold increase in bai gene cluster abundance (r = 0.609). Conjugated bile acids show a dose‐response relationship with hepatocellular carcinoma risk (OR = 1.28–5.62), while late breakfast increases gallstone risk (OR = 1.435). The combination of dried blood spot sampling (R2 > 0.92) and AI‐based prediction models (AUC = 0.82–0.90) offers a feasible approach for dynamic monitoring. Conclusions This review proposes a three‐tiered stratified management strategy—DBS sampling, targeted metabolomics, and AI assessment—to provide a clinical translational reference for early warning and precision prevention of gallstones and hepatobiliary tumours.
SN - 2768-0622
ER -